Enterome

Executive Summary

Enterome is a clinical-stage biopharmaceutical company pioneering the discovery of immunomodulatory drugs derived from the gut microbiome for cancer treatment. Founded in 2012 and headquartered in Paris, the company leverages its proprietary platform to identify OncoMimics™ peptides—molecules that mimic tumor antigens to elicit potent and durable anti-tumor immune responses. This unique approach positions Enterome at the intersection of microbiome science and immuno-oncology, targeting a range of solid tumors with the potential for improved efficacy and safety profiles compared to conventional immunotherapies. The company's lead candidate, EO-2401, is a novel microbiome-based immunotherapy designed to stimulate the immune system against multiple tumor-associated antigens. Enterome has advanced this program into Phase 2 clinical trials, demonstrating its commitment to translating microbiome insights into tangible therapies. With ongoing collaborations and a robust pipeline, Enterome represents a promising player in the rapidly evolving field of microbiome-based therapeutics.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 Data Readout for EO-2401 in Advanced Solid Tumors45% success
• Q3 2026FDA Fast Track Designation or Orphan Drug Status60% success
• Q4 2026New Partnership or Licensing Agreement for Microbiome Platform70% success